ProQR Therapeutics (PRQR) Common Equity (2021 - 2025)

ProQR Therapeutics' Common Equity history spans 4 years, with the latest figure at $94.6 million for Q4 2024.

  • For Q4 2024, Common Equity rose 112.5% year-over-year to $94.6 million; the TTM value through Dec 2024 reached $94.6 million, up 112.5%, while the annual FY2024 figure was $95.9 million, 114.09% up from the prior year.
  • Common Equity for Q4 2024 was $94.6 million at ProQR Therapeutics, up from $44.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $130.5 million in Q4 2021 and bottomed at $44.5 million in Q4 2023.
  • The 4-year median for Common Equity is $81.3 million (2024), against an average of $84.4 million.
  • The largest annual shift saw Common Equity crashed 47.88% in 2022 before it skyrocketed 112.5% in 2024.
  • A 4-year view of Common Equity shows it stood at $130.5 million in 2021, then plummeted by 47.88% to $68.0 million in 2022, then crashed by 34.54% to $44.5 million in 2023, then skyrocketed by 112.5% to $94.6 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Common Equity are $94.6 million (Q4 2024), $44.5 million (Q4 2023), and $68.0 million (Q4 2022).